Treatment

Early Daratumumab Monotherapy Delays Progression in High-Risk Smoldering Myeloma

Researchers of the phase 3 Aquila study presented at the 66th ASH Annual Meeting and showed that daratumumab (D) monotherapy significantly delays progression in patients with high-risk smoldering...
CURATED BY: Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Cilta-cel Enhances Quality of Life and Delays Symptoms in Refractory Myeloma

Researchers of a phase 3 trial evaluated patient-reported outcomes from the CARTITUDE-4 study, comparing ciltacabtagene autoleucel (cilta-cel) with standard-of-care regimens in patients with lenalidomide-refractory multiple myeloma....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Interconnected Burdens: Fatigue, Sleep, Mood, and Function in Newly Diagnosed Multiple Myeloma

Patients newly diagnosed with multiple myeloma (MM) often present with anemia, fatigue, sleep disturbances, pain, and mood disruption—all of which impact quality of life and functional performance....
CURATED BY:
Jill N. Burke,
CNP, DipACLM

Frailty Assessments in Personalized Treatment for Older Adults with Multiple Myeloma: A Case Study

Authors of this article discuss the role of frailty assessments in managing older adults with multiple myeloma (MM). Frailty scores, including the IMWG score, are valuable tools for predicting treatment...
CURATED BY:
Jill N. Burke,
CNP, DipACLM

Dupilumab Effectively Manages Lenalidomide-Induced Rash in Patients With Multiple Myeloma

Lenalidomide (Len) is a crucial treatment for multiple myeloma (MM), improving progression-free survival (PFS), but it often causes a rash that leads to dose reductions or interruptions. Len rash occurs...
CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Real-World Analysis of Lenalidomide-Refractory Multiple Myeloma

Lenalidomide combination therapy is commonly used for patients with newly diagnosed and relapsed/refractory multiple myeloma (MM)....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Advancing Care for High-Risk Myeloma: Tailored Strategies and Innovative Therapies

Despite significant advancements in multiple myeloma (MM) treatment, high-risk (HR) and ultrahigh-risk (uHR) populations remain underserved, with poorer outcomes and shorter survival....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN
Share